Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has announced the granting of 42,082 restricted stock units (RSUs) to three newly hired employees. These RSUs are set to vest in four equal annual installments, starting from the grant date and continuing until the fourth anniversary.
The grants were made under the company's 2024 Inducement Stock Incentive Plan and are in accordance with Nasdaq Listing Rule 5635(c)(4). This rule allows for the granting of equity as a material inducement for new employees to join the company. Vesting of these equity awards is contingent upon the employees' continued service with Solid Biosciences through each vesting date.
Solid Biosciences Inc. (Nasdaq: SLDB), un'azienda delle scienze della vita che si concentra sulla sviluppo di medicinali genetici di precisione per le malattie neuromuscolari e cardiache, ha annunciato l'assegnazione di 42.082 unità di azioni vincolate (RSU) a tre nuovi dipendenti assunti. Queste RSU saranno conferite in quattro rate annuali uguali, a partire dalla data di concessione e continuando fino al quarto anniversario.
Le concessioni sono state effettuate nell'ambito del Piano d'Incentivazione Azionaria per Induzione 2024 della società e sono conformi alla Regola di Quotazione Nasdaq 5635(c)(4). Questa regola consente l'assegnazione di partecipazioni azionarie come incentivo materiale per i nuovi dipendenti che si uniscono all'azienda. L'acquisizione di questi premi azionari è subordinata al continuo servizio dei dipendenti con Solid Biosciences fino a ciascuna data di acquisizione.
Solid Biosciences Inc. (Nasdaq: SLDB), una empresa de ciencias de la vida enfocada en desarrollar medicamentos genéticos de precisión para enfermedades neuromusculares y cardíacas, ha anunciado la concesión de 42,082 unidades de acciones restringidas (RSUs) a tres empleados recién contratados. Estas RSUs se otorgarán en cuatro cuotas anuales iguales, comenzando desde la fecha de concesión y continuando hasta el cuarto aniversario.
Las concesiones se realizaron bajo el Plan de Incentivos de Acciones por Inducción 2024 de la empresa y están de acuerdo con la Regla de Cotización de Nasdaq 5635(c)(4). Esta regla permite la concesión de capital como un incentivo material para que nuevos empleados se unan a la empresa. La adquisición de estos premios en acciones está condicionada a la continuidad del servicio de los empleados con Solid Biosciences hasta cada fecha de adquisición.
Solid Biosciences Inc. (Nasdaq: SLDB)는 신경근육 및 심장 질환을 위한 정밀 유전자 치료제를 개발하는 생명 과학 회사로, 세 명의 새로 채용된 직원에게 42,082개의 제한된 주식 단위(RSU)를 부여한다고 발표했습니다. 이 RSU는 부여일로부터 시작하여 4회의 동일한 연간 할부로 배분될 예정입니다.
부여는 회사의 2024년 유인 주식 인센티브 계획에 따라 이루어졌으며, 나스닥 상장 규칙 5635(c)(4)에 일치합니다. 이 규칙은 신입 직원이 회사에 입사하도록 유인하기 위해 자본을 부여할 수 있도록 허용합니다. 이러한 주식 보상의 취득은 각 취득일마다 Solid Biosciences와 지속적으로 근무해야만 가능합니다.
Solid Biosciences Inc. (Nasdaq: SLDB), une entreprise de sciences de la vie axée sur le développement de médicaments génétiques de précision pour les maladies neuromusculaires et cardiaques, a annoncé l'octroi de 42 082 unités d'actions restreintes (RSU) à trois nouveaux employés. Ces RSU devraient être acquises en quatre versements annuels égaux, à partir de la date d'octroi et se poursuivant jusqu'au quatrième anniversaire.
Les octrois ont été réalisés dans le cadre du Plan d'Incentive en Actions par Induction 2024 de l'entreprise et sont conformes à la Règle d'Inscription Nasdaq 5635(c)(4). Cette règle permet d'octroyer des capitaux propres comme incitation matérielle pour que les nouveaux employés rejoignent l'entreprise. L'acquisition de ces récompenses en actions dépend du service continu des employés avec Solid Biosciences jusqu'à chaque date d'acquisition.
Solid Biosciences Inc. (Nasdaq: SLDB), ein Unternehmen der Lebenswissenschaften, das sich auf die Entwicklung von präzisen genetischen Medikamenten für neuromuskuläre und kardiale Erkrankungen konzentriert, hat die Gewährung von 42.082 eingeschränkten Aktieneinheiten (RSUs) an drei neu eingestellte Mitarbeiter bekannt gegeben. Diese RSUs sollen in vier gleichen jährlichen Raten nach dem Gewährungsdatum und bis zum vierten Jahrestag ausgezahlt werden.
Die Gewährungen erfolgten im Rahmen des 2024 Incentive Stock Plan des Unternehmens und entsprechen der Nasdaq Listungsregel 5635(c)(4). Diese Regel erlaubt die Gewährung von Eigenkapital als materielle Anreiz für neue Mitarbeiter, um dem Unternehmen beizutreten. Die Vesting dieser Eigenkapitalprämien ist an den fortgesetzten Dienst der Mitarbeiter bei Solid Biosciences bis zu jedem Vestingdatum gebunden.
- Attraction of new talent with equity incentives
- Alignment of employee interests with company performance through RSU grants
- Potential dilution of existing shareholders' equity
CHARLESTOWN, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 42,082 restricted stock units (“RSUs”) to three newly hired employees.
The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s continued service with the Company through each applicable vesting date.
These grants were made pursuant to the Company’s 2024 Inducement Stock Incentive Plan and were made as an inducement material to each employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
FAQ
How many restricted stock units (RSUs) did Solid Biosciences (SLDB) grant to new employees?
What is the vesting schedule for the RSUs granted by Solid Biosciences (SLDB)?
Under which plan were the RSUs granted by Solid Biosciences (SLDB)?
What is the purpose of the RSU grants made by Solid Biosciences (SLDB)?
